Aytu Bioscience (NASDAQ:AYTU) announced its earnings results on Thursday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.37), Bloomberg Earnings reports. Aytu Bioscience had a negative return on equity of 110.91% and a negative net margin of 217.45%. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.58 million.
Shares of NASDAQ AYTU opened at $1.03 on Friday. The company has a market cap of $8.89 million, a P/E ratio of -0.04 and a beta of 4.96. Aytu Bioscience has a 1 year low of $0.68 and a 1 year high of $50.00.
Separately, Northland Securities began coverage on shares of Aytu Bioscience in a research report on Monday, October 22nd. They set an “outperform” rating and a $10.00 target price on the stock.
COPYRIGHT VIOLATION WARNING: This piece was published by Macon Daily and is the sole property of of Macon Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://macondaily.com/2019/02/09/aytu-bioscience-aytu-announces-earnings-results-misses-expectations-by-0-37-eps.html.
Aytu Bioscience Company Profile
Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.
Featured Story: What does relative strength index mean?
Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.